Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

Bio_Be_Dirty Oct. 22 at 10:20 PM

$CUE babies going places

0 · Reply

Invest2live Oct. 21 at 2:55 PM

$SPRO 73% already; checkout $IBIO and $CUE

0 · Reply

Invest2live Oct. 21 at 1:53 PM

$CLYM $IBIO $NGD $IBIO 50% already; congrats 🎊 🌿🎈 Checkout $CLYM and $CUE and $LCTX

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

Invest2live Oct. 16 at 4:32 PM

$NGD 1010% already; congrats 🎉 🎈🎊 Like if you still kept the shares; check out $CUE and $IPSC; do your DD and get in. Remember that these are biotech stocks and don’t put all your eggs in one basket.

0 · Reply

Invest2live Oct. 15 at 5:59 PM

$BITF 512% already; congrats 🎈 🎉🎊 Checkout $IBIO and $CUE; do your DD and get in.

0 · Reply

BadyBady Oct. 15 at 12:33 PM

$IOBT 😎😍😍😍 $CUE $TNYA

0 · Reply

BadyBady Oct. 15 at 9:11 AM

$IOBT BooooM CC: $TNYA $CUE $EZGO

1 · Reply

CalculatedSwing Oct. 15 at 1:14 AM

$BIVI 🚀 $BIVI is primed for liftoff! Phase 2b Parkinson's data incoming + liver Fast Track = massive catalysts ahead. Low float bio with 500% potential—don't sleep! Watching peers $CUE $INMB $ACAD $KPTI for sector rotation. #Biotech #BIVI

1 · Reply

Invest2live Oct. 14 at 1:48 PM

$GNPX 14% already; congrats 🎈 🎊🎉 Movement in the correct direction. Checkout $HRMY and $CUE

1 · Reply

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Aug 21, 2025, 8:00 AM EDT - 2 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 2 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 2 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 3 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 4 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 4 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 5 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 6 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 6 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 6:12 PM EDT - 6 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 2:00 AM EDT - 6 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 6 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:05 PM EDT - 6 months ago

Cue Biopharma Announces Proposed Public Offering

Apr 14, 2025, 5:02 PM EDT - 6 months ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 7 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 11 months ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 11 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Mar 21, 2023, 11:00 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Bio_Be_Dirty Oct. 22 at 10:20 PM

$CUE babies going places

0 · Reply

Invest2live Oct. 21 at 2:55 PM

$SPRO 73% already; checkout $IBIO and $CUE

0 · Reply

Invest2live Oct. 21 at 1:53 PM

$CLYM $IBIO $NGD $IBIO 50% already; congrats 🎊 🌿🎈 Checkout $CLYM and $CUE and $LCTX

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

Invest2live Oct. 16 at 4:32 PM

0 · Reply

Invest2live Oct. 15 at 5:59 PM

$BITF 512% already; congrats 🎈 🎉🎊 Checkout $IBIO and $CUE; do your DD and get in.

0 · Reply

BadyBady Oct. 15 at 12:33 PM

$IOBT 😎😍😍😍 $CUE $TNYA

0 · Reply

BadyBady Oct. 15 at 9:11 AM

$IOBT BooooM CC: $TNYA $CUE $EZGO

1 · Reply

CalculatedSwing Oct. 15 at 1:14 AM

1 · Reply

Invest2live Oct. 14 at 1:48 PM

$GNPX 14% already; congrats 🎈 🎊🎉 Movement in the correct direction. Checkout $HRMY and $CUE

1 · Reply

Invest2live Oct. 13 at 8:14 PM

$PLX 153% already; congrats 🎉 🎈🎊 Checkout $CUE and $CLYM

0 · Reply

Invest2live Oct. 13 at 7:03 PM

$BITF 412% already; congrats 🎈🎉🎊 Checkout $CUE and $LCTX

1 · Reply

BadyBady Oct. 13 at 2:01 PM

$CUE Toward 1$ 😎

0 · Reply

BadyBady Oct. 13 at 11:35 AM

$IOBT $TNYA $CUE $IOBT 😎😍

1 · Reply

Invest2live Oct. 11 at 3:13 PM

$DRRX 246% already; congrats 🎊 🎉🎈 Checkout $CUE and $LCTX

0 · Reply

BadyBady Oct. 10 at 6:17 PM

$CUE $TNYA $IOBT Trump would make us rich—he’d escalate tensions with China, stocks would crash, and within a week at most, he’d reconcile and the market would bounce back. What happened during his presidency —those were golden opportunities. 😍

0 · Reply

Invest2live Oct. 10 at 4:48 PM

$BITF 350% already; congrats 🎊 🎈🎉 Checkout $GNPX and $CUE

0 · Reply

Arcides Oct. 10 at 3:54 PM

$CUE 3 previos days gains gone in a while...

0 · Reply

curt20011 Oct. 9 at 7:57 PM

$CUE Let's keep the momentum going! Buying more before it pops!

0 · Reply

topstockalerts Oct. 9 at 5:33 PM

Cue Biopharma shares rose Thursday, extending recent gains after the 2025 Nobel Prize in Physiology or Medicine recognized breakthroughs in immune regulation that align closely with the company’s CUE-401 development program. The Nobel was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries in peripheral immune tolerance and regulatory T cells (Tregs), validating the scientific foundation of Cue’s approach to treating autoimmune diseases. CUE-401 uses a dual IL-2/TGF-β mechanism designed to restore immune balance by expanding Tregs while suppressing pathogenic effector cells. Preclinical data have shown that the molecule can induce potent and stable Tregs, suggesting broad potential across multiple autoimmune indications. $CUE

0 · Reply

TradingL101 Oct. 9 at 4:04 PM

$CUE

0 · Reply

Invest2live Oct. 9 at 3:43 PM

$CUE 50% already; congrats 🎈 🎉🎊 Checkout $GOVX and $GTEC for longs

0 · Reply

Market Cap	59.96M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-437.78%
Debt to Equity Ratio	0.14

Volume	91,900
Avg Vol	195,046
Day's Range	N/A - N/A
Shares Out	76.85M
Stochastic %K	34%
Beta	1.55
Analysts	Strong Sell
Price Target	$4.00